Qingkailing Suppresses the Activation of BV2 Microglial Cells by Inhibiting Hypoxia/Reoxygenation-Induced Inflammatory Responses

Mana, Lulu; Wang, Shan; Zhu, Haiyan; Xing, Yanwei; Lou, Lixia; Wu, Aiming; Dong, Bin; Sun, Yikun; Yang, Shuo; Wang, Lin; Gao, Yonghong

doi:https://doi.org/10.1155/2014/696218

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results Discussion Acknowledgments References Copyright Related Articles

Special Issue

Bioactives and Traditional Herbal Medicine for the Treatment of Cardiovascular/Cerebrovascular Diseases

View this Special Issue

Research Article | Open Access

Volume 2014 | Article ID 696218 | https://doi.org/10.1155/2014/696218

Qingkailing Suppresses the Activation of BV2 Microglial Cells by Inhibiting Hypoxia/Reoxygenation-Induced Inflammatory Responses

Lulu Mana,¹Shan Wang,²Haiyan Zhu,¹Yanwei Xing,³Lixia Lou,¹Aiming Wu,¹Bin Dong,¹Yikun Sun,¹Shuo Yang,⁴Lin Wang,⁵and Yonghong Gao¹

Academic Editor: Joen-Rong Sheu

Received13 Nov 2013

Accepted02 Apr 2014

Published28 Apr 2014

Abstract

Qingkailing (QKL) is a well-known composite extract used in traditional Chinese medicine. This extract has been extensively administered to treat the acute phase of cerebrovascular disease. Our previous experiments confirmed that QKL exerts an inhibitory effect on cerebral ischemia-induced inflammatory responses. However, whether QKL suppresses the activation of microglia, the primary resident immune cells in the brain, has yet to be determined. In this study, BV2 microglial cells were used to validate the protective effects of QKL treatment following ischemia-reperfusion injury simulated via hypoxia/reoxygenation in vitro. Under these conditions, high expression levels of ROS, COX-2, iNOS, and p-p38 protein were detected. Following ischemia/reperfusion injury, QKL significantly increased the activity of BV2 cells to approximately the basal level by modulating microglial activation via inhibition of inflammatory factors, including TNF-α, COX-2, iNOS, and p-p38. However, QKL treatment also displayed dose-dependent differences in its inhibitory effects on p38 phosphorylation and inflammatory factor expression.

1. Introduction

Ischemic cerebrovascular disease (ICVD) is a notably common clinical cerebrovascular disease. The mechanisms underlying cerebral ischemia-reperfusion injury are quite complicated. Oxidative stress and the inflammatory response are considered to be the key mediators of cerebral ischemic injury. The injury and repair mechanisms in anoxic and ischemic environments, which are mediated by the abnormally activated microglia, have become a recent target of neurological research field. Unfortunately, these mechanisms have yet to be fully elucidated. The specific mechanism by which microglia become activated in response to cerebral ischemia remains controversial [1, 2]. When ischemia occurs, microglia are rapidly activated initially in response to the stressful stimulus. Studies have revealed that activated microglia can protect neurons via phagocytic removal of pathogens and dead cell debris, as well as secretion of neurotrophic factors [3–5].

However, additional evidence has indicated that activated microglia can also synthesize and release inflammatory mediators, leading to neuronal dysfunction and death, in response to injury and stimulation [6, 7]. Abnormally activated microglia can damage neurons by releasing proinflammatory cytokines, inflammation-related enzymes, and chemokines and activating NADPH oxidase to generate reactive oxygen species, induce the expression of IL-1, TNF- and MMP-9, promote leukocyte infiltration, and weaken the blood-brain barrier [8]. Because of their rapid activation and their important roles in oxidative stress and the inflammatory response, microglia may represent a new line of investigation in the search for a clinical therapy for cerebral ischemia.

Qingkailing (QKL) is a modified extract from a traditional Chinese medicine, An-Gong-Niu-Huang Pill. It is composed of Radix Isatidis, Flos Lonicerae, Concha Margaritifera Usta, baicalin, Fructus gardeniae, cholic acid, hyodeoxycholic acid, and Cornu Bubali [9]. QKL injection has been widely used clinically to treat the acute phase of cerebrovascular disease and has displayed excellent efficacy in improving neurological function [10, 11]. We and other investigators demonstrated that QKL injection can improve neurological function, decrease the expression of adhesion molecules, inhibit inflammatory responses, and partially restore BBB function in a rat model of brain ischemia/reperfusion injury [12–15].

Based on the findings described above, we speculated that QKL might modulate the inflammatory response mediated by activated microglia. BV2 microglial cells were used as a model, and in vitro hypoxia/reoxygenation was performed to simulate ischemia/reperfusion in vivo. The roles of the inflammatory factors TNF-, iNOS, and COX-2 and the regulatory function of the corresponding signaling pathways are also examined.

2. Materials and Methods

2.1. Materials

MTT and dimethyl-sulfoxide (DMSO) were obtained from Solarbio Corporation, China. The mouse TNF- ELISA Kit was purchased from Neobioscience Co., Ltd., China. Trizol reagent was purchased from Invitrogen Corporation, USA. The Reverse Transcription System (A3500 kit) was purchased from Promega Corporation, USA. The Power SYBR Green PCR Master Mix kit was purchased from ABI Corporation, USA. RIPA Lysis Buffer, Super ECL Plus Detection Reagent, Prestained Protein Marker (10-170KD), proteinase inhibitor cocktail, PhosSTOP phosphatase inhibitor, and the ROS detection kit (product no: C1300) were purchased from Applygen Technologies Co., Ltd. COX-2 (H-62) and iNOS (N-20) were purchased from Santa Corporation, USA. The mouse anti--actin and HRP-labeled goat anti-rabbit IgG antibodies were purchased from Wuhan Boster Biological Technology, Ltd. The p-p38 and p38/β (H-147) antibodies were purchased from Beijing ZhongShan-Golden Bridge Biological Technology Co., Ltd., China. Minocycline was purchased from Sigma Corporation, USA. QKL was purchased from Yabao Beizhongda (Beijing) Pharmaceutical Co., Ltd., China.

2.2. Cell Culture and the Hypoxia-Reoxygenation Injury Model

2.2.1. Cell Culture

Mouse microglial BV2 cells were purchased from the cell culture center at the Institute of Basic Medical Sciences (IBMS) of the Chinese Academy of Medical Sciences (CAMS). The cells were suspended in culture medium specialized for microglia (DMEM containing 10% fetal bovine serum, 100 U/mL penicillin, and 100 U/mL streptomycin). At 80% confluency, the cells were passaged using trypsin-EDTA solution (0.05% trypsin and 0.02% EDTA).

2.2.2. Establishment of the In Vitro BV2 Cell Hypoxia/Reoxygenation Model

BV2 cells were digested into a cell suspension, and the cell density was adjusted to cells/mL. After 80% confluence, the cells were washed 3 times with PBS, replaced with serum-free DMEM medium, and placed in a three-gas incubator at 37°C containing 1.0% O₂ to initiate hypoxia, followed by reoxygenation in an incubator at 37°C containing 5% CO₂.

2.2.3. Evaluation of the BV2 Cell Viability

The MTT method was used to assess cell viability. Cell viability was measured using an enzyme-labeling instrument at 492 nm. The hypoxia duration was 12 hours, while reoxygenation occurred for 12 or 24 hours.

2.2.4. ROS Assay Using Flow Cytometry

The BV2 cells were cultured in a six-well plate at a density of cells/mL. The cells were digested and harvested following exposure to normoxia or 12 h of hypoxia followed by 12 h of reoxygenation. Then, the cells were incubated in 1 mL of DCFH-DA (10 μmol/L) for 30 minutes. The cells were washed three times with PBS and analyzed via flow cytometry (Beckman Co., FC50).

2.3. Effects of QKL on BV2 Cell Viability after Hypoxia/Reoxygenation

2.3.1. Cell Group

The experiment comprised six groups: a control group (the cells were cultured normally in serum-free DMEM); the model group (12 h of hypoxia and 12 h of reoxygenation in serum-free DMEM medium); the low, medium, and high QKL groups (a final QKL concentration of 0.0625%, 0.125%, or 0.25%, resp., in serum-free DMEM was added before hypoxia); and the minocycline group (200 nmol/L minocycline was added before hypoxia).

2.3.2. MTT Assay the Changes of Cell Viability

The hypoxia duration was 12 hours, while reoxygenation lasted for 12 hours. The MTT method was used to assess cell viability, as described above.

2.4. Effect of QKL on the Concentration of TNF- in the Supernatant of BV2 Cells Subjected to Hypoxia/Reoxygenation

The groups assigned were the same as above. The cell supernatants were collected and stored at −80°C. ELISA was performed to measure the TNF- concentration in the cell culture supernatants.

2.5. Effect of QKL on Inflammatory Cytokine (COX-2 and iNOS) mRNA Expression in BV2 Cells Subjected to Hypoxia/Reoxygenation

Real-time quantitative polymerase chain reaction (real-time PCR) was performed to evaluate the mRNA expression of COX-2 and iNOS. The mRNA was extracted, reverse-transcribed, and quantified via real-time PCR. The following PCR primers were used: COX-2 (191 bp), forward: 5′-GATGACTGCCCAACTCCC-3′; reverse: 5′-AACCCAGGTCCTCGCTTA-3′. iNOS (95 bp), forward: ′-CAGCTGGGCTGTACAAACCTT-3′; reverse: 5′-CATTGGAAGTGAAGCGTTTCG-3′. -actin (185 bp), forward: 5′-AGGCCAACCGTGAAAAGATG-3′; reverse: ′-TGGCGTGAGGGAG A GCATAG-3′.

The cycling conditions were 50°C for 2 min and initial denaturation at 95°C for 10 min, followed by 40 cycles at 95°C for 30 s and 55°C for 30 s. The data were analyzed using the Stratagene MX3000P System. The levels of COX-2 and iNOS mRNA normalized to that of -actin were compared between the different groups.

2.6. Effect of QKL on Inflammatory Factor (COX-2 and iNOS) Protein Expression in BV2 Cells and on the p38 Signaling Pathway during Ischemia-Reperfusion Injury In Vitro

After reoxygenation, the cells were washed 3 times with PBS, followed by pipetting repeatedly in RIPA Lysis Buffer. Then, the cellular protein extract was collected. The proteins were separated via 10% SDS-PAGE and transferred to nitrocellulose membranes, which were subsequently incubated in a primary antibody to COX-2, iNOS, p-p38, or p38 (1 : 1000) at 4°C overnight. After the membranes were washed three times with TBST, they were further incubated in the appropriate horseradish peroxidase-conjugated secondary antibody for 2 hours at room temperature. Then, ECL visualization was performed. NIH Image J was used to calculate the gray values. The intensity of the target protein was normalized to that of an internal reference to determine the relative expression level of the target protein.

2.7. Statistical Analysis

The data were expressed as the means ± SD. Statistical analysis was performed via one-way analysis of variance (ANOVA) using SPSS11.0 software. was considered to be significant.

3. Results

3.1. Establishment of the In Vitro Hypoxia/Reoxygenation Model

Based on inverted phase contrast microscopy, approximately 60–80% of the cells in the control group were well-anchored contained, a polygonal cell body; approximately 20–40% of the cells were suspended. As hypoxia continued, the cell body gradually became rounded, and the attached cells became suspended and gathered into clusters. Hypoxia for 12 h resulted in significant changes compared to the control group, and these changes were exacerbated after reoxygenation for 24 h (Figure 1(a)). MTT colorimetry suggested that, compared to the control group, after hypoxia for 12 h followed by reoxygenation for 12 h or 24 h in an three-gas incubator, the number of surviving BV2 cells in the model group were significantly reduced () (Figure 1(b)). As shown in Figure 1(c), the level of ROS in the model group (hypoxia for 12 h and reoxygenation for 12 h) was significantly higher than the normal group ().

(a)

(b)

(c)

Figure 1

Effects of different durations of hypoxia/reoxygenation on BV2 microglia cells. (a) BV2 cells were exposed to hypoxia for 6 or 12 hours followed by reoxygenation for 12 hours. Morphological changes were observed under an inverted microscope (100). (b) After exposure to hypoxia for 12 hours, the BV2 cells were reoxygenated for 12 or 24 hours. Cell viability was assed using the MTT method. Each value indicates the mean ± SD. . compared to the control group. (c) ROS level in BV2 microglial cells after hypoxia for 12 hours and reoxygenation for 12 hours based on flow cytometry. . compared to the control group.

Based on the comparisons of the cellular morphology and viability after different hypoxia durations, we chose 12 h of hypoxia and 12 h of reoxygenation, which caused significant injury, for the simulation of ischemia-reperfusion injury in vitro.

3.2. QKL Increased Cell Viability in BV2 Microglia Exposed to 12 Hours of Hypoxia and 12 Hours of Reoxygenation

Based on the model establishment above, according to the results of pilot experiments, the nontoxic dose range of QKL treatment was chosen to be 0.0625%, 0.125%, and 0.25% (Figure 2). Alternatively, 200 nmol/L minocycline, the specific inhibitor of microglia, was applied prior to hypoxia. The results revealed that the value of the cells treated with any of the three concentrations of QKL or minocycline, which were exposed to hypoxia for 12 h and reoxygenation for 12 h, was significantly higher than the model group. This result confirmed that QKL remarkably increases BV2 cell survival and activation under ischemia-reperfusion conditions, reverting them to control levels, preventing both the activation and injury of BV2 cells.

3.3. QKL Decreased the Expression of TNF- in BV2 Cell Supernatants

TNF- is an important inflammatory factor that is released after microglial activation that plays an important role in nerve inflammation. The results (Figure 3) revealed that compared to the control group, the concentration of TNF- in the model group was significantly increased (). Treatment with 0.0625%, 0.125%, or 0.25% QKL or 200 nmol/L minocycline significantly reduced TNF- production induced by hypoxia/reoxygenation compared to the model group (). Together, these results indicated that ischemia-reperfusion injury activates BV2 cells to produce a large quantity of TNF-, which participates in the inflammatory response induced by ischemia reperfusion. QKL blocked microglial activation by inhibiting TNF- expression.

3.4. QKL Decreased the Expression of COX-2 and iNOS

Activated microglia can also damage neurons by releasing proinflammatory cytokines, inflammation related enzymes, and so on. We performed real-time PCR and Western blot analyses to examine the changes in the expression of COX-2 and iNOS (Figures 4(a) and 4(b)). After hypoxia for 12 hours and reoxygenation for 12 hours, the mRNA and protein expression levels of COX-2 and iNOS were significantly increased. Treatment with 0.25% QKL or 200 nmol/L minocycline significantly decreased the mRNA expression level compared to the model group. However, treatment with 0.25% QKL clearly decreased the protein expression of COX-2 and iNOS in BV2 cells exposed to hypoxia/reoxygenation. In addition, treatment with 0.125% QKL also decreased the protein expression of iNOS in BV2 cells. Together, these results demonstrate that QKL alleviates the increases in COX-2 and iNOS expression, protecting against further ischemia-reperfusion caused by protein and gene expression. Importantly, these results are consistent with those of the cell viability and TNF- expression assays described above.

(a)

(b)

3.5. QKL Inhibited p38 Phosphorylation in BV2 Cells Exposed to Hypoxia/Reoxygenation

To further elucidate whether the p38 signaling pathway affects the expression of iNOS and COX2 in BV2 cells, we measured the expression of phosphorylated p38 protein and analyzed the ratio of p-p38 to p38. As shown in Figure 5, the control group expressed a small amount of p-p38 protein, and p-38 expression was significantly increased in the model group. Treatment with 0.0625% QKL or 200 nmol/L minocycline significantly decreased p-p38 protein expression in BV2 cells subjected to hypoxia/reoxygenation compared to the model group ().

(a)

(b)

4. Discussion

As one of the primary mechanisms of cerebral ischemia, the inflammatory response can cause secondary brain injury. Inflammatory cytokines, which are released from so-called inflammatory cells such as neutrophils, granulocytes, lymphocytes, and glia, can stimulate the adherence of leukocytes to the vascular endothelium, induce inflammatory responses, and cause tissue edema, destroying brain tissue [3–5].

Previous studies have demonstrated that, whether under the conditions of diseases or culture systems, the primary source of proinflammatory cytokines is microglia rather than astrocytes. Moreover, IL-1 and TNF- have been suggested to be the most important proinflammatory cytokines in this process [16]. The massive expression of TNF- acts as a key mediator of cerebral ischemia-induced inflammation, which cannot only mediate a cascade of inflammatory responses but also amplify inflammation by interacting with other inflammatory factors, thus inducing the expression of adhesion molecules on the endothelium as well as other inflammatory mediators by macrophages, endothelial cells, and spongiocytes. TNF- induces the migration of activated leukocytes to the ischemic area, and these cells release free radicals, causing secondary injury [17, 18]. Furthermore, TNF- itself can enhance the activation of microglia [19, 20].

Based on the findings of our study, after hypoxia for 12 h followed by reoxygenation for 12 h, the levels of ROS increased and the concentration of TNF- in the cell culture supernatant was significantly increased, but cell viability decreased. Treatment with the high, middle, or low concentration of QKL clearly inhibited the expression of TNF- and increased cell viability.

iNOS and COX-2 are suggested to be important factors involved in microglial activation and critical mediators of cerebral ischemic injury caused by microglia. When reperfusion occurs, a large amount of oxygen molecules gathers in the cerebral ischemia area, which react with NO to produce powerful oxidants that can cause irreversible oxidative damage to cells [21]. An iNOS gene knock-out mouse model exhibited a significant decrease in the infarct volume following middle cerebral artery occlusion [22]. NADPH is a multisubunit enzyme complex; once NADPH becomes activated, ROS, a second messenger of cell signal transduction, is strongly produced, which leads to the activation of the p38-MAPK signaling pathway and the expression of proinflammatory cytokines (e.g., TNF-) and inflammation-related enzymes (e.g., iNOS and COX-2) [23, 24]. Conversely, NADPH is specifically activated by these cytokines, thus promoting the production of ROS and other inflammatory factors. In this manner, a vicious cycle of ever-increasing neurotoxins is initiated, ultimately resulting in neuronal necrosis [25].

In our experiments, increases in the mRNA and protein expression levels of both COX-2 and iNOS in BV2 microglia were induced by hypoxia/reoxygenation. Treatment with the low or middle concentration of QKL displayed a significant effect on the protein expression of COX-2. The inhibitory effects of the high concentration of QKL on the mRNA and protein expression of iNOS and COX-2 were the most significant, which demonstrated that the inhibitory effects of QKL on the inflammatory response became stronger as the QKL concentration increased.

Studies have indicated that oxidative stress, TNF-, and so forth [4], via the p38 MAPK signaling pathway in conjunction with other signaling pathways, modulate the gene expression and activity of enzymes in response to cell stress, and it is hypothesized that protein phosphorylation is necessary for the activation of these pathways and the progression of signal transduction [26]. In our study, the low concentration of QKL significantly reduced the expression of p-p38 protein in BV2 cells subjected to hypoxia/reoxygenation. However, this effect is not equivalent to its effect on the expression of levels of COX-2 and iNOS. Together, these results indicate that QKL exerts different actions at varying concentrations. The high concentration of QKL significantly inhibited microglial activation, but it may also affect other signaling pathways. However, there were dose-dependent differences in the inhibition of p38 phosphorylation and inflammatory cytokine expression that merit further examination.

Conflict of Interests

All authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Lulu Mana, Shan Wang, Haiyan Zhu, Yanwei Xing, Lixia Lou, and Aiming Wu contributed equally to this paper.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Grant no. 81173229) and the independent subject of Beijing University of Chinese Medicine (no. 2011-JYB ZZJS-001).

References

E. D. Milligan and L. R. Watkins, “Pathological and protective roles of glia in chronic pain,” Nature Reviews Neuroscience, vol. 10, no. 1, pp. 23–36, 2009.
View at: Publisher Site | Google Scholar
U.-K. Hanisch and H. Kettenmann, “Microglia: active sensor and versatile effector cells in the normal and pathologic brain,” Nature Neuroscience, vol. 10, no. 11, pp. 1387–1394, 2007.
View at: Publisher Site | Google Scholar
W. Liu, Y. Tang, and J. Feng, “Cross talk between activation of microglia and astrocytes in pathological conditions in the central nervous system,” Life Sciences, vol. 89, no. 5-6, pp. 141–146, 2011.
View at: Publisher Site | Google Scholar
K. Helmut, U.-K. Hanisch, M. Noda, and A. Verkhratsky, “Physiology of microglia,” Physiological Reviews, vol. 91, no. 2, pp. 461–553, 2011.
View at: Publisher Site | Google Scholar
C. N. Parkhurst and W.-B. Gan, “Microglia dynamics and function in the CNS,” Current Opinion in Neurobiology, vol. 20, no. 5, pp. 595–600, 2010.
View at: Publisher Site | Google Scholar
M. L. Block and J.-S. Hong, “Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism,” Progress in Neurobiology, vol. 76, no. 2, pp. 77–98, 2005.
View at: Publisher Site | Google Scholar
H.-M. Gao and J.-S. Hong, “Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression,” Trends in Immunology, vol. 29, no. 8, pp. 357–365, 2008.
View at: Publisher Site | Google Scholar
B. H. Buck, D. S. Liebeskind, J. L. Saver et al., “Early neutrophilia is associated with volume of ischemic tissue in acute stroke,” Stroke, vol. 39, no. 2, pp. 355–360, 2008.
View at: Publisher Site | Google Scholar
B. U. o. C. Medicine, “The study of novel dosage form of An Gong Niu Huang Wan,” Journal of New Medicine, vol. 12, p. 8, 1975.
View at: Google Scholar
F. Cheng, W. Song, S. Guo, D. Wang, and Q. Wang, “Meta-analysis of clearing heat and removing toxicity therapy on ischemic stroke,” Pharmacology and Clinics of Chinese Materia Medica, vol. 27, no. 1, pp. 106–109, 2011.
View at: Google Scholar
C. Li, X. Wang, and S. Chen, “Clinical study on acute upper respiratory tract infection treated with qingkailing injection,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 19, no. 4, pp. 212–214, 1999.
View at: Google Scholar
Y. Gao, Z. Yuan, F. Niu, L. Zhu, P. Li, and S. Wang, “Effect of new QingKaiLing injection on adhesion molecules expression of an in vitro ischemia and reperfusion injury model of rat brain microvascular endothelial cell,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 23, no. 3, pp. 197–199, 2008.
View at: Google Scholar
H. Zhu, L. Chi, B. Xu, Y. Gao, and J. Lou, “Effect of qingkailing injection on blood brain barrier permeability in hypoxia condition,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 18, no. 9, pp. 35–37, 2011.
View at: Google Scholar
L. Lv, Y. Liu, H.-F. Shi, and Q. Dong, “Qingkailing injection attenuates apoptosis and neurologic deficits in a rat model of intracerebral hemorrhage,” Journal of Ethnopharmacology, vol. 125, no. 2, pp. 269–273, 2009.
View at: Publisher Site | Google Scholar
J. Li, R. G. Wu, F. Y. Meng et al., “Synergism and rules from combination of Baicalin, Jasminoidin and Desoxycholic acid in refined Qing Kai Ling for treat ischemic stroke mice model,” PLoS ONE, vol. 7, no. 9, Article ID e45811, 2012.
View at: Google Scholar
J. V. Welser, L. Li, and R. Milner, “Microglial activation state exerts a biphasic influence on brain endothelial cell proliferation by regulating the balance of TNF and TGF-β1,” Journal of Neuroinflammation, vol. 7, article 89, 2010.
View at: Publisher Site | Google Scholar
C. Gong, Z. Qin, A. L. Betz, X.-H. Liu, and G.-Y. Yang, “Cellular localization of tumor necrosis factor alpha following focal cerebral ischemia in mice,” Brain Research, vol. 801, no. 1-2, pp. 1–8, 1998.
View at: Publisher Site | Google Scholar
M. Minami, Y. Kuraishi, K. Yabuuchi, A. Yamazaki, and M. Satoh, “Induction of interleukin-1β mRNA in rat brain after transient forebrain ischemia,” Journal of Neurochemistry, vol. 58, no. 1, pp. 390–392, 1992.
View at: Google Scholar
B. Becher, A. Prat, and J. P. Antel, “Brain-immune connection: immuno-regulatory properties of CNS-resident cells,” Glia, vol. 29, no. 4, pp. 293–304, 2000.
View at: Google Scholar
S. Nadeau and S. Rivest, “Role of microglial-derived tumor necrosis factor in mediating CD14 transcription and nuclear factor κ B activity in the brain during endotoxemia,” Journal of Neuroscience, vol. 20, no. 9, pp. 3456–3468, 2000.
View at: Google Scholar
M. Koch and J. De Keyser, “Uric acid in multiple sclerosis,” Neurological Research, vol. 28, no. 3, pp. 316–319, 2006.
View at: Publisher Site | Google Scholar
P. L. Huang, “Nitric oxide and cerebral ischemic preconditioning,” Cell Calcium, vol. 36, no. 3-4, pp. 323–329, 2004.
View at: Publisher Site | Google Scholar
L. Zhang, C. Wu, S. Zhao et al., “Demethoxycurcumin, a natural derivative of curcumin attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-κB signaling pathways in N9 microglia induced by lipopolysaccharide,” International Immunopharmacology, vol. 10, no. 3, pp. 331–338, 2010.
View at: Publisher Site | Google Scholar
K.-J. Min, H.-K. Pyo, M.-S. Yang, K.-A. Ji, I. Jou, and E.-H. Joe, “Gangliosides activate microglia via protein kinase C and NADPH oxidase,” Glia, vol. 48, no. 3, pp. 197–206, 2004.
View at: Publisher Site | Google Scholar
M. L. Block and J. S. Hong, “Chronic microglial activation and progressive dopaminergic neurotoxicity,” Biochemical Society Transactions, vol. 35, no. 5, pp. 1127–1132, 2007.
View at: Publisher Site | Google Scholar
R.-R. Ji, R. W. Gereau IV, M. Malcangio, and G. R. Strichartz, “MAP kinase and pain,” Brain Research Reviews, vol. 60, no. 1, pp. 135–148, 2009.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2014 Lulu Mana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

2205

Downloads

1037

Citations